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Summary In discussions on breast cancer screening, much attention has been focussed on the possible
morbidity generated by screening. Favourable effects like the prevention of advanced disease seem underes-
timated, probably because quantification is that difficult. To analyse the amount of care and treatment given
to women with advanced breast cancer, we report on patients followed from first recurrence until death using
patient files and national sources. A random sample of 60 female cases from computerised registries of two
cancer centres and a sample of 20 cases from a non-computerised hospital registry was taken. A total of 68
patient files were sufficiently documented. A woman with advanced breast cancer is estimated to have a 39%
loss in utility compared to a healthy woman (range 27-45%). Hormonal treatment is the main modality
during 14 and chemotherapy during 4 months. Total medical cost from diagnosis of advanced disease until
death amounts to 17,100 US dollars, or 21,000 when including extramural cost.
The effect of breast cancer screening by preventing the occurrence of advanced disease is quantified. The
resulting gain in quality of life contributes 70% of the total gain in quality of life. In the long run, almost half
of the annual cost of screening will be offset by savings in the cost for advanced disease. Only the changes in
palliative surgery and/or radiotherapy will be small in contrast to primary treatment changes. Besides the
mortality reduction, screening is justified by the improvements in quality of life and cost savings for women
prevented from reaching advanced disease.
Population screening for breast cancer has been introduced
in several countries. Trials have shown that it is possible to
reduce breast cancer mortality by mammographic screening
of women of 50 years and older (Wald et al., 1991). The
seemingly less favourable mortality reductions achieved in
two trials (Andersson et al., 1988; Roberts et al., 1990)
resulted in articles that emphasise possible disadvantages of
breast cancer screening, and attention has been focussed on
the morbidity generated (Roberts, 1989; Dixon & John,
1992). However, the impact of screening on the prevention of
advanced disease and its morbidity is generally neglected. In
contrast to the research in costs and possible adverse effects
of screening (Ellman et al., 1989), the impact on the preven-
tion of morbidity had not yet been analysed in detail nor
quantified.
Little is known about the actual amount of care and
treatment given to all women with advanced breast cancer,
because of the wide variety, which makes it difficult to
estimate the actual impact of screening on this group. Most
published case series relate to disease-free or post-recurrence
survival only. For this reason, we conducted a detailed study
on systemic and palliative treatments using breast cancer
patient files and using national sources from the Netherlands.
It provides an overview of advanced disease and its course
and identifies types and durations of diagnostic and treat-
ment procedures, amount of care involved and the associated
medical cost. At the same time, we calculated quality of life
estimates for the different forms of palliative care. There has
been extensive investigation into the psychological sequelae
of early breast cancer and its treatment, but few data concer-
ning patients with advanced disease (Hopwood et al., 1991).
In this paper, population effects of screening with respect
to the prevention of advanced disease are illustrated by
simulating two different screening policies and calculating its
impact on three aspects: morbidity (by a quality of life-
index), consequences for health care and for medical cost.
These are related to the other favourable and unfavourable
effects and to the cost changes of screening. As a result, the
consequenes for clinical practice in this area may now be
related to the changes in primary treatment due to screening.
Patients and methods
Patient files (both in- and out-patient) were analysed from
three public hospitals in the Netherlands: Antoni van Leeu-
wenhoek cancer centre (Amsterdam), Dr Daniel den Hoed
cancer centre (Rotterdam) and Sint Anna Hospital (Oss).
The first two have computerised data on all breast cancer
patients diagnosed since 1981. The third is a general hospital,
in which similar (non-computerised) data have been collected
since 1973. From the two computerised registries, 60 female
cases which met following criteria: (a) died from breast
cancer in the period 1985-1989, (b) had received primary
treatment with curative intent, (c) first diagnosis of breast
cancer between the ages 50 and 80, were randomly taken. All
20 available female cases from the smaller hospital which met
criteria (a) and (b) were used. All patients had developed
distant metastases. A total of 68 patient files (see Table I)
were sufficiently documented to follow the full course of
patient's illness. Data regarding the actual palliative and/or
systemic treatment (in these or other hospitals) were recorded
from the date of first diagnosis of advanced disease (distant
metastases and/or locoregional recurrence after mastectomy)
up to the date of death. These included hospital admissions,
duration and dosage of medication, surgery, type and dura-
tion of radiotherapy, and diagnostic and pathological proce-
dures, excluding items clearly not related to the disease. Data
of one patient with a local recurrence after breast conserving
therapy were included from the moment that the (second)
recurrence after ablative surgery had been diagnosed.
Literature on quality of life for women with advanced
breast cancer was collected as part of a larger study on breast
cancer screening and quality of life. A total of 15 phases,
including screening, primary treatment, etc. have been inves-
tigated (de Haes et al., 1991). Advanced disease was divided
into five episodes: those in which respectively hormonal treat-
ment, chemotherapy, palliative radiotherapy or surgery is the
main treatment modality, and in a terminal phase. A ques-
tionnaire was constructed in which the complaints and symp-
toms, found in 39 articles were summarised for these five
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TableI Maincharacteristicsofpatients(a),primarytumour(b),primarytreatment(c),andfirstrecurrence
(d) from 68 women who died from breast cancer in 1985-1989. Three hospitals
(a) Number of women from hospital
Mean age at first diagnosis of breast cancer
(b) Postoperative TN pT1, pT2
pT3, pT4, pT.
pNo, pN+, pNx
Oestrogen receptor positive ( 10 fmol mg')
negative
unknown
(c) Mastectomy
Breast conserving therapy
Postoperative radiotherapy
Adjuvant chemotherapy
Adjuvant hormonal treatment
(d) Locoregional recurrence
Distant metastases: bone
lung
liver
other
Disease free interval (mean)
(median)
1
2
3
28%, 56%
12%, 1%,3%
25%, 72%, 3%
60%
24%
16%
79%
21%
93%
10%
3%
15%
44%
23%
9%
9%
24
21
21
27
20
61 (32-76)
months (1.5-81)
months
episodes of advanced breast cancer, considering the three
dimensions physical, psychological and social. Eighteen pub-
lic health professionals and 13 breast cancer experts were
asked to value each of the described episodes on a visual
analogue scale (VAS). The best health state is assumed to
have a value of 1, whereas the worst state has a zero value.
For quality-adjusted life-year analysis, the utility measure
should reflect the subject's willingness to trade off quality
against length of life, which is the case when using the
so-called 'standard gamble' or 'time trade off' technique.
Scores on direct scaling methods such as the VAS are
systematically lower, but have been found to be related by a
power function to the scores of the 'time trade off' method.
Time Trade Off= 1-(1-VAS)'82 (Bombardier et al., 1982).
Using this function, the utilities for the five different states
were computed from the scores of the direct scaling method.
The average loss in quality of life for female breast cancer
patients with advanced disease was calculated by combining
the utilities with the mean durations of the different disease
episodes found in the 68 patients.
Calculations of costs have been restricted to direct medical
cost and were based on the detailed data from the files. Only
the exact number of out-patient visits, if patients did not
receive chemotherapy, was estimated (Holli et al., 1989).
Actual cost was calculated for radiotherapy. Cost for medical
procedures and out-patient visits were based on the most
recent Dutch tariffs. Cost of hormonal treatment and chemo-
therapy was based on (cheapest) retail-prices of the drugs
and a fixed amount per prescription and calculated for the
exact dosages and durations prescribed. Costs are expressed
in US dollars using purchasing-power parities (1990, 1 US
dollar = 2 Dfl). Cost of hospital nursing was based on the
mean number of in-patient days, as analysed in our file
study, and the mean all-out tariff in the Netherlands of 235
US dollars per day (Dutch Sickness Funds Association,
1990). Cost for spending a day in a nursing home is 100 US
dollars, but 235 US dollars in the terminal phase. Three
sources were used to analyse the representativeness of the
hospital files. A questionnaire was sent to all 20 Dutch
radiotherapy departments, concerning the number of female
breast cancer patients that had been treated by radiation for
recurrences or distant metastases in the years 1986-1988.
Data concerning all hospital admissions in the Netherlands
for women with breast cancer during 1985-1988 and data on
80% of the admissions to nursing homes in 1986-1988 (Cen-
tre for Health Care Information) were analysed to obtain
independent estimates of the number of in-patient days.
The MISCAN breast cancer model was used to predict the
decrease in the number of women with advanced disease and
in breast cancer mortality when introducing nationwide
screening in the Netherlands (van Oortmarssen et al., 1990).
It is assumed in the model that all women, who had (or
would have) died from breast cancer, had or would have
been treated for advanced disease. Key parameters of this
model were derived from an analysis of all results from the
Dutch screening trials (de Koning et al., 1991). The improve-
ment in prognosis after early detection was based on the
33% reduction (weighted average) in breast cancer mortality
achieved in the randomised trials in Kopparberg/Oster-
gotland (Tabar et al., 1989) and in Malm6 (Andersson et al.,
1988) after 8-9 years for women in the study group aged
50-70 assuming a trial situation of 70% attendance and a
2-year interval. Effects are presented in this article for 2-
yearly screening for women aged 50-70 (Dutch policy) and
for 3-yearly for women aged 50-65 (Vessey, 1991) (atten-
dance rate 70%). Cases of advanced disease that are pre-
vented by screening are assumed to be a random subset ofall
cases of advanced disease. The overall impact of the screen-
ing programme, including unfavourable effects and favour-
able effects other than the prevention of advanced disease,
have been taken into account but are described elsewhere in
detail (de Koning et al., 1991; de Haes et al., 1991).
Results
Systemic andpalliative treatment
Hormonal treatment was the first-line treatment in 57% of
all women with advanced disease and chemotherapy in only
16%. Most patients received more than one treatment moda-
lity during the period from recurrence till death. Out-patient
drug treatment was the most frequently applied modality:
84% of women received hormonal treatment and 69% re-
ceived chemotherapy during one or more time periods (Table
II). Tamoxifen, aminoglutethimide, high dose progestins and
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) were
used most frequently. If Tamoxifen had been prescribed to a
woman, she had taken it during 9.5 months on average.
Aminoglutethimide, mostly used in the second or third line,
and CMF were prescribed for respectively 6 and 5.5 months
on average. In the lower part of the Table, figures are
averaged out over all 68 women: drug treatment is the main
modality during 18 months.
Radiotherapy, especially effective in reducing pain and
invalidity caused by bone metastases, had been given to 59%952 H.J. DE KONING et al.
Table II Synopsis of treatment and amount of health care for women with advanced
breast cancer from first recurrence until death (thus excluding primary therapy)
(a) First measure hormonal treatment 57%
radiotherapy 19%
chemotherapy 16%
surgery 6%
none 2%
At least once hormonal treatment 84%
chemotherapy 69%
radiotherapy 59%
(b) Number of hospital admissions
Total in-patient days (mean)
(median)
Total days in nursing home
Duration of hormonal treatment
Duration ofchemotherapy
Diagnostic procedures X-rays
isotopic scans
CT
pathological procedures
Post-recurrence survival period till death (mean)
(median)
2.5
45
40
8.3
14 months
4 months
22
2
0.8
1.9
21.4 months (0.5-70.5)
20.3 months
(a) all women, (b) average per woman, based on 68 patient files from three hospitals.
of the women. Surgery played only a minor part in treatment
and had often been undertaken with diagnostic intent. Dur-
ing the period of advanced disease, women remained in
hospital for a mean period of one and a half months. The
period from first recurrence until death was on average 21.4
months. Figure 1 shows the survival curve from the month of
first recurrence of all 68 women. The three patient groups
from the separate centres show a striking resemblance. The
mean post-recurrence survival is 19.7 months in hospital 1,
21.7 months in hospital 2 and 22.7 months in hospital 3 (not
significantly different; log-rank test).
Quality oflife
The experts' assessment on quality of life did not in general
differ significantly from that of the other persons (health
professionals), both in ranking order and in mean or median
value (de Haes et al., 1991). Only palliative hormonal treat-
ment was considered to have less impact on quality of life by
the clinicians than by the non-clinicians (Table III, bl versus
b2). An ANOVA (analysis ofvariance) showed no systematic
difference between the two groups of respondents, which was
the reason for combining the values in all further calculations
(b3-e). Using the questionnaires of 27 respondents, this
results in (combined) median values between 0.45 for ad-
vanced breast cancer in a period with mainly hormonal
treatment and 0.17 for the terminal phase.
Months
-- hospital 1 - - -- hospital 2 . hospital 3
'2
all cases
Figure 1 Post-recurrence survival of 68 female breast cancer
patients. No significant differences (log-rank test). Note: death of
breast cancer was a selection criterium in this study.
Each row in Table III represents the loss in quality of life
for a patient with advanced disease in relation to each of the
treatment episodes and to the terminal period. The Table
shows that a woman in the terminal period has a 71% loss in
utility as compared to a healthy woman (column c) and the
length of this period is 3 to 4 weeks on average (column d).
In the preceding episodes, the utility is calculated to be
34-47% lower compared to a healthy woman with a larger
loss in quality of life in the order: hormonal treatment,
palliative surgery, radiotherapy and chemotherapy. The rela-
tively long duration of hormonal treatment influences the
overall quality of life strongly. A woman with advanced
breast cancer is estimated to have a quality of life which is on
average 39% lower compared to that of healthy women
during 21 months which corresponds to 1.75-0.68 = 1.07
quality = adjusted life-year with advanced disease. The lower
and upper limits for this loss in quality of life, based on the
extreme mean or median values in either of the respondent
groups, are 27% and 45% respectively.
Cost oftreatment
Total intramural medical cost from diagnosis of advanced
disease until death amounted to an average of 17,100 US
dollars per woman, of which 62% is attributable to hospital
nursing (Table IV). Radiation therapy (9%) was used fre-
quently but mostly for a relatively short period (6.9 sessions
per palliative radiation treatment). Diagnostic testing is also
costly (10%); e.g. approximately one X-ray was made every
month to follow the course of metastases or to find the
source of complaints (Table II). The other 19% are cost for
out-hospital visits to specialists, cost of drugs and cost for
Table III Calculation ofthe impact ofadvanced breast cancer and its
treatment on quality of life
a bi b2 b3 c d e
Hormonal treatment 0.59 0.37 0.45 0.34 1.16 0.39
Palliative surgery 0.47 0.40 0.41 0.38 0.10* 0.04
Radiotherapy 0.38 0.38 0.38 0.41 0.08 0.03
Chemotherapy 0.34 0.34 0.34 0.47 0.33 0.16
Terminal stage 0.19 0.16 0.17 0.71 0.08 0.06
Total period 1.75 0.68
Disease episode considered (a), median values on a visual analogue
scale(bI -3), (I-utility)-measure correspondingto b3 applicabletoeach
period (c), duration oftreatment as found in file study in years (d) and
the loss in quality of life years during each phase (e = c x d).
*Approximation based on in-patient days. bl = breast cancer experts.
b2 = health professionals. b3 = combined.
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Table IV Mean medical cost for women treated for advanced breast
cancer based on 68 patient files (extramural cost not included)*
Hospital nursing 10,575.- 62%
Diagnostic procedures 1,700.- 10%
Radiation treatment 1,626.- 9%
Nursing home 1,250.- 7%
Hormonal treatment 760.- 5%
Specialists 640.- 4%
Chemotherapy 550.- 3%
Total per woman 17,100.- 100%
Mean cost in US dollars per woman based on all patients. Mean
durationofdisease 21.4months. *Extramural costperwoman: 3860US
dollars.
nursing homes. Despite the fact that medication is the most
frequently applied treatment modality in advanced disease, it
is responsible for only 8% of the total cost.
Impact ofnationwide screening
With ten 2-yearly invitations for screening to women between
ages 50 and 70, total breast cancer mortality is expected to be
reduced by 16% in the Dutch population. However, it takes
considerable time before this reduction will be reached. With-
out a screening programme, the total number of women that
will die from breast cancer will rise to approximately 4245 in
the year 2014. Screening will lower this figure by 655 in that
year. As nearly all women with breast cancer in an advanced
stage will ultimately die from the disease, the number of new
patients for treatment of advanced disease will decrease
proportionally to the expected decrease in breast cancer mor-
tality. Table V summarises the impact of nationwide screen-
ing in the Netherlands, especially concerning the prevention
of advanced disease in the year 2014. The lower breast cancer
mortality as a result of the Dutch screening policy reflects
6630 life-years gained in 2014. In addition (655 x 1.75 = )
1150 women-years with the diagnosis of and treatment for
advanced breast cancer will be prevented, which is apart
from the life-years gained the second most important favour-
able effect of screening.
By including the gain in 440 Quality = Adjusted Life-Years
(QALY's) due to prevented advanced disease, screening as a
whole leads to a relatively minor overall impact on quality of
life. Unfavourable effects of screening are responsible for a
decrease in quality of life of 10%, due to the loss in quality
of life during the screening examination ( + 85) and in (more)
treatment and follow up (+ 570). However, it is almost
entirely counterparted by the gain in quality of life due to the
prevention of advanced breast cancer. The total number of
QALY's (6425) is 3% lower than the total number of life-
years gained (6630).
The lower part of Table V states the screening and total
medical cost for all new women who will need assessment,
primary treatment or treatment for advanced breast cancer in
2014. In the absence of screening, the cost for treating all
women with advanced disease is (4245 x $21,000 = ) 90 mln
US dollars when including extramural cost. This represents
42% of total expenditures related to breast cancer. Forty-
seven per cent of the annual cost of screening (30 mln US
dollars) will be offset by savings due to a decrease in the need
to treat women with advanced disease ( = 14 mln US dol-
lars). If costs generated by screening (false positives, more
primary treatment and longer follow up) are taken into
account, one third of the cost of screening will be counter-
parted by savings. The impact on the demand for health care
services is another aspect. The decrease in systemic and
palliative treatments results in a prevention ofdrug treatment
and in a decrease in hospital admissions and in-patient days,
primarily noticed by the physician in internal medicine. How-
ever, changes in palliative surgical procedures or radio-
therapeutic sessions will be small, which is quite in contrast
to the large and immediate changes in primary treatment as a
result of the implementation of screening (de Koning et al.,
1990).
The consequences of a 3-yearly screening interval for
women aged 50-65 (UK policy) if implemented in the
Netherlands are presented in the right column. The smaller
age range invited is responsible for a 28% lower number of
breast cancer deaths prevented. Due to the fact that women
will have less screens with a 3-year interval (given the same
time period), the number of prevented treatments will be
reduced by another 13%, resulting in a total of 405 (versus
655 in the other policy). But again, the impact of preventing
advanced disease on the total effects and expenditures is
clear: 275 quality = adjusted life-years are gained due to less
advanced disease and even 44% of the annual cost of screen-
ing are offset.
For both policies in Table V, the estimated mortality
reduction is based on the reduction achieved in Kopparberg/
Osterg6tland and Malm6, which implies a 33% reduction in
the age group 50-70 for a 2-year and a 21% reduction in the
age group 50-65 for a 3-year interval programme with 70%
attendance rate. The recent update of screening trials
indicates an approximately 25% reduction, if the HIP-trial
Table V Impact of nationwide breast cancer screening on prevention of advanced disease
Difference Difference
No screening 50-70 (2yr) 50-70 (2yr) 50-65 (3yr)
Number of new patients with advanced disease 4245 3590 - 655 - 405
Total life-years gained 6630 4460
QALY-adjustment, due to:
Screening 0 85 + 85 + 45
Assessment 135 125 -10 - 15
Primary treatment/follow up 6700 7270 + 570 + 335
Advanced disease 2900 2460 - 440 - 275
Total + 205 + 90
Total quality-adjusted life-years (QALY's) gained 6425 4370
Total cost of:
Screening 0 30 + 30 + 18
Assessment 47 45 -2 -2
Primary treatment/follow up 76 82 + 6 + 3
Advanced disease 90 76 -14 -9
Total 213 233 + 20 + 10
Change in number ofnewpatients, inquality oflife and incost (inmln USdollars). Year2014 for threesituations: without
screening, 2-yearly screening ofwomen aged 50-70 (and difference), and difference with respectively 3-yearly screening of
women aged 50-65. Costs are annual total costs for all applicable women in the Netherlands. No discounting.954 H.J. DE KONING et al.
(Health Insurance Plan of Greater New York) and the
TEDBC (UK Trial of Early Detection of Breast Cancer) are
included and the actual differences in screening interval or
attendance rate are neglected (Wald et al., 1991). We have
considered the HIP-results to be too outdated for predicting
the effect of present European programmes. In our estimate,
we corrected the results of both Swedish randomised trials
for the specific differences in age groups, screening interval,
attendance rate, follow up period, and trial size. Considering
the other point estimates on mortality reduction, the
'Swedish average' appears a realistic one (de Koning et al.,
1991).
Discussion
Average treatment
A comparison with literature and some national data was
made to check whether the selection of patient files had not
resulted in a serious bias. One of the main prognostic dis-
criminants is the site and number ofmetastases, which makes
it difficult to compare (inter-) national data deriving from
different hospitals. Nevertheless, median post-recurrence sur-
vival is mostly in the range of 18-24 months (Powles et al.,
1980; Patel et al., 1986; Tomin & Donegan, 1987; Perez et
al., 1990; Dixon et al., 1991), which strongly resembles our
data (20.3 mo). Almost 60% of the women in the three
hospitals had received radiation treatment for advanced
disease. Our national survey amongst radiotherapy depart-
ments indicated that approximately 1925 female patients had
been radiated in 1988 for advanced breast cancer, which is
also approximately 60% of the annual number of women
that died from breast cancer. In general, these data support
our findings from the file study.
Literature on the cost of treating women with advanced
disease is scarce. In the Netherlands, de Waard had analysed
52 files of women treated in 1973-74 for primary breast
cancer, who had developed metastases in the 10 years after
(de Waard et al., 1986). With tariffs based on the public
health insurance scheme, which are lower than those for
privately insured patients, the cost of treating metastases was
calculated to be US 16,000 (total duration of disease un-
known). The average number of in-patient days was 66 in
that time period, which highly influenced the cost. The lower
number of 45 in our study is certainly a reflection of the
policy in the eighties of not admitting all women to hospital
for chemotherapy anymore. Medicare data from the United
States have shown that the cost of care for breast cancer
patients delivered during the last 6 months of life are 15,137
US dollars (Baker et al., 1991). Cost for continuing care in
the months before is 483 US dollars per month, but this is
not just attributable to cancer. A baseline estimate for all
Medicare patients was 235 US dollars per month. Total
breast cancer expenditure for women surviving 21 months
can be calculated to be approximately 19,000 US dollars.
Cost of treatment will remain uncertain, as the most important part of the cost is related to the number of in-
patient days. Our analysis on all national admissions to
hospital shows fewer in-patient days (in the range of 35 to
40), which is more in line with the median number of days in
our patient files, but one can not select as specifically to
advanced breast cancer as one is able to do with actual patient files. The same applies to in-patient days in nursing
homes, although the national data are very close to those in
the file study (9.5 instead of 8.3 days). However, in general
our cost analysis is a moderate estimate, as cost for anal-
gesics, expenditure incurred by patients and their families or
extramural cost have not been included in the file study.
Furthermore, the cost of medication was based on the
cheapest retail prices. A separate analysis has shown that
extramural cost are at least 3860 US dollars per woman.
Total cost for women treated for advanced breast cancer
would then become approximately 21,000 US dollars, which
resembles the scarce international data quite well.
Uncertainties
The years that mass screening will have a significant impact
on diminishing the number of treatments for advanced
disease are at least 5-10 years ahead. New treatment mod-
alities like hyperthermia, new systemic therapies, use of
haematological growth factors with chemotherapy or modali-
ties interfering with growth factor-receptor interaction may
have reached a more mature stage then and changed treat-
ment policies and results. The current increase in the use of
adjuvant Tamoxifen in many countries, resulting in a possi-
ble decrease of the number of women suffering from ad-
vanced disease (Early Breast Cancer Trialists' Collaborative
Group, 1992) is a good example. Criticism may also be
expressed on the calculated savings due to mass screening, as
women whose advanced breast cancer has been prevented
will have a chance of getting other diseases and use other
medical resources. Furthermore, our direct scaling method
should in the future be adapted for measurements in patients.
We have not used different utilities for different age groups.
The relationship between age at time of disease and utility is
not clear cut. Some studies do find a relationship, others do
not. Furthermore, if changes are found, they may be in
different directions for each dimension (Cassileth et al., 1984;
Nerenz et al., 1986; de Haes et al., 1990). Nevertheless, our
study does provide insight in the changes to be expected, at
present, due to nationwide, screening.
Whether our results will be applicable to other countries
will depend on four important factors. The number of in-
patient days and the percentage ofwomen treated with radia- tion are the most influential two factors for total costs. There
may be differences between countries on these points. For instance, terminally ill breast cancer patients in Finland
appeared to have been treated significantly less by radiation
(Holli et al., 1989). Recording the total durations of hor-
monal treatment and chemotherapy will be important for
quality of life. Finally, the fourth and most important factor
is the breast cancer mortality reduction that can be expected
in different countries when implementing nationwide screen-
ing, as this is implicitly related to the prevention of advanced disease and its treatment, the savings and the gain in quality
of life.
In overview, the impact of breast cancer screening with
respect to the prevention of advanced disease and its mor-
bidity is evident. In the long term, high quality screening will
result in an important benefit for the women involved and in
a considerable reduction of the amount of effort and money
being spent to treat women with advanced disease. As long
as there is no treatment highly effective against advanced disease, breast cancer screening will play an important role.
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